Cas:4623-25-0 5-bromo-1,3-dimethyl-2,6-dioxopyrimidine-4-carboxylic acid manufacturer & supplier

We serve Chemical Name:5-bromo-1,3-dimethyl-2,6-dioxopyrimidine-4-carboxylic acid CAS:4623-25-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-bromo-1,3-dimethyl-2,6-dioxopyrimidine-4-carboxylic acid

Chemical Name:5-bromo-1,3-dimethyl-2,6-dioxopyrimidine-4-carboxylic acid
CAS.NO:4623-25-0
Synonyms:1,3-Dimethyl-5-bromorotsaeure;5-bromo-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid;1,3-Dimethyl-5-bromoorotic acid
Molecular Formula:C7H7BrN2O4
Molecular Weight:263.04500
HS Code:2933599090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:310.5ºC at 760 mmHg
Density:1.913g/cm3
Index of Refraction:1.627
PSA:81.30000
Exact Mass:261.95900
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,3-Dimethyl-5-bromorotsaeure chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3-Dimethyl-5-bromoorotic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3-Dimethyl-5-bromoorotic acid Use and application,1,3-Dimethyl-5-bromoorotic acid technical grade,usp/ep/jp grade.


Related News: Charles River looks forward to continuing its ongoing partnership with AstraZeneca. It was great to join the team today, to see the facility for myself and congratulate them on this really significant expansion, which will see an €8m investment, creating 90 new jobs for Mayo. 5,6-dihydro-4H-1,2-oxazine manufacturers After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million. 5-[(4-Methyl-N-phenyl-piperazine-1-carboximidoyl)-amino]-3,4-diphenyl-thieno[2,3-c]pyridazine-6-carboxylic acid ethyl ester suppliers Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful. 2-Piperidinecarboxylic acid, 1-[(4-nitrophenyl)sulfonyl]- vendor & factory.